{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:44:07Z","timestamp":1790253847043,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"crossref","award":["2016\/04105-0"],"award-info":[{"award-number":["2016\/04105-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Indoleamine 2, 3-dioxygenase-1 (IDO1) is a promising target for immunotherapy in bladder cancer (BC). IDO1 breaks-down tryptophan to generate kynurenine derivatives, which may activate the aryl hydrocarbon receptor (AHR). AHR is an important target for carcinogens, but its association with BC progression was unknown. Two IDO1 inhibitors used in clinical trials are 1-methyl-D-tryptophan (MT) and INCB240360. Because MT is an aromatic hydrocarbon, it may be a ligand for AHR. We hypothesized that AHR could be associated with BC progression and that MT could activate AHR in BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      BC patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009165) were selected from the Gene Expression Omnibus database. A cut-off point for relative expression of AHR and cytochrome 450 enzymes (CYP1A1, CYP1A2, and CYP1B1; markers of AHR activation) was determined to compare with the grade, stage, and tumor progression. For in vitro experiments, RT4 (grade 1) and T24 (grade 3) BC cells were incubated with MT and INCB240360 to evaluate the expression of AHR and CYP1A1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AHR activation was associated with grade, stage, and progression of BC. T24 cells express more CYP1A1 than RT4 cells. Although IDO1 expression and kynurenine production are elevated in T24 cells concomitantly to CYP1A1 expression, IDO1 inhibitors were not able to decrease CYP1A1 expression, in contrast, MT significantly increased it in both cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, it is rational to inhibit IDO1 in BC, among other factors because it contributes to AHR activation. However, MT needs to be carefully evaluated for BC because it is an AHR pathway agonist independently of its effects on IDO1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07371-6","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T08:32:44Z","timestamp":1599726764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression"],"prefix":"10.1186","volume":"20","author":[{"given":"Luiz Henrique Gomes","family":"Matheus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Vanin","family":"Dalmazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Barbosa Oliveira","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson Jos\u00e9","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleber Pinto","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-3671","authenticated-orcid":false,"given":"Humberto","family":"Dell\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"issue":"1","key":"7371_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96\u2013108.","journal-title":"Eur Urol"},{"issue":"1","key":"7371_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.bbrc.2005.08.162","volume":"338","author":"Y Fujii-Kuriyama","year":"2005","unstructured":"Fujii-Kuriyama Y, Mimura J. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochem Biophys Res Commun. 2005;338(1):311\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"7371_CR3","doi-asserted-by":"publisher","first-page":"e12557","DOI":"10.1111\/jpi.12557","volume":"66","author":"JW Lv","year":"2019","unstructured":"Lv JW, Zheng ZQ, Wang ZX, et al. Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types. J Pineal Res. 2019;66(3):e12557.","journal-title":"J Pineal Res"},{"issue":"5","key":"7371_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/ijms20051016","volume":"20","author":"U Jeschke","year":"2019","unstructured":"Jeschke U, Zhang X, Kuhn C, et al. The prognostic impact of the aryl hydrocarbon receptor (AhR) in primary breast Cancer depends on the lymph node status. Int J Mol Sci. 2019;20(5):1016.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"7371_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ijc.29398","volume":"137","author":"M Ishida","year":"2015","unstructured":"Ishida M, Mikami S, Shinojima T, et al. Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke. Int J Cancer. 2015;137(2):299\u2013310.","journal-title":"Int J Cancer"},{"issue":"2","key":"7371_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/em.20588","volume":"52","author":"KT Chung","year":"2011","unstructured":"Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen. 2011;52(2):81\u2013104.","journal-title":"Environ Mol Mutagen"},{"issue":"4","key":"7371_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1084\/jem.20020052","volume":"196","author":"P Terness","year":"2002","unstructured":"Terness P, Bauer TM, R\u00f6se L, Dufter C, Watzlik A, Simon H, Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196(4):447\u201357.","journal-title":"J Exp Med"},{"issue":"5380","key":"7371_CR8","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","volume":"281","author":"DH Munn","year":"1998","unstructured":"Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281(5380):1191\u20133.","journal-title":"Science."},{"key":"7371_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","volume":"336","author":"GC Prendergast","year":"2018","unstructured":"Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and its therapeutic inhibition in Cancer. Int Rev Cell Mol Biol. 2018;336:175\u2013203.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"7371_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ucl.2019.09.013","volume":"47","author":"CE Chu","year":"2020","unstructured":"Chu CE, Porten SP, Grossfeld GD, Meng MV. Role of Indoleamine-2,3-Dioxygenase inhibitors in salvage therapy for non-muscle invasive bladder Cancer. Urol Clin North Am. 2020;47(1):111\u20138.","journal-title":"Urol Clin North Am"},{"issue":"54","key":"7371_CR11","doi-asserted-by":"publisher","first-page":"91914","DOI":"10.18632\/oncotarget.20166","volume":"8","author":"HC Lewis","year":"2017","unstructured":"Lewis HC, Chinnadurai R, Bosinger SE, Galipeau J. The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells. Oncotarget. 2017;8(54):91914\u201327.","journal-title":"Oncotarget."},{"issue":"Database issue","key":"7371_CR12","first-page":"D991","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(Database issue):D991\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"7371_CR13","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","volume":"28","author":"JS Lee","year":"2010","unstructured":"Lee JS, Leem SH, Lee SY, Kim SC, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28(16):2660\u20137.","journal-title":"J Clin Oncol"},{"key":"7371_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3 Published 2010 Jan 8.","journal-title":"Mol Cancer"},{"issue":"1","key":"7371_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer."},{"issue":"12","key":"7371_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3846","volume":"14","author":"IA Murray","year":"2014","unstructured":"Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14(12):801\u201314.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"7371_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.21873\/anticanres.14076","volume":"40","author":"J Yu","year":"2020","unstructured":"Yu J, Lu Y, Muto S, Ide H, Horie S. The dual function of aryl hydrocarbon receptor in bladder carcinogenesis. Anticancer Res. 2020;40(3):1345\u201357.","journal-title":"Anticancer Res"},{"issue":"1","key":"7371_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-017-0636-5","volume":"16","author":"A Al-Dhfyan","year":"2017","unstructured":"Al-Dhfyan A, Alhoshani A, Korashy HM. Aryl hydrocarbon receptor\/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and \u03b2-Catenin and Akt activation. Mol Cancer. 2017;16(1):69.","journal-title":"Mol Cancer"},{"issue":"10","key":"7371_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/mnfr.200600006","volume":"50","author":"S Knerr","year":"2006","unstructured":"Knerr S, Schrenk D. Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. Mol Nutr Food Res. 2006;50(10):897\u2013907.","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"7371_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/0008-5472.CAN-09-3090","volume":"70","author":"Y Fan","year":"2010","unstructured":"Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010;70(1):212\u201320.","journal-title":"Cancer Res"},{"key":"7371_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/carcin\/bgl179","volume":"28","author":"WA Fritz","year":"2007","unstructured":"Fritz WA, Lin TM, Cardiff RD, Peterson RE. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis. 2007;28:497\u2013505.","journal-title":"Carcinogenesis."},{"key":"7371_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2121-10-27","volume":"10","author":"TL Peng","year":"2009","unstructured":"Peng TL, Chen J, Mao W, Song X, Chen MH. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol. 2009;10:27 Published 2009 Apr 16.","journal-title":"BMC Cell Biol"},{"issue":"4","key":"7371_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0006-291X(02)02970-4","volume":"300","author":"T Niermann","year":"2003","unstructured":"Niermann T, Schmutz S, Erne P, Resink T. Aryl hydrocarbon receptor ligands repress T-cadherin expression in vascular smooth muscle cells. Biochem Biophys Res Commun. 2003;300(4):943\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"7371_CR24","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.yexcr.2006.08.002","volume":"312","author":"T Ikuta","year":"2006","unstructured":"Ikuta T, Kawajiri K. Zinc finger transcription factor slug is a novel target gene of aryl hydrocarbon receptor. Exp Cell Res. 2006;312(18):3585\u201394.","journal-title":"Exp Cell Res"},{"issue":"6","key":"7371_CR25","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","volume":"185","author":"JD Mezrich","year":"2010","unstructured":"Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190\u20138.","journal-title":"J Immunol"},{"key":"7371_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bbrc.2008.07.156","volume":"375","author":"CF Vogel","year":"2008","unstructured":"Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun. 2008;375:331\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7368","key":"7371_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197\u2013203.","journal-title":"Nature."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07371-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T19:23:57Z","timestamp":1631129037000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07371-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7371"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07371-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-31922\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-31922\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-31922\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"869"}}